Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
Identifieur interne : 001851 ( Istex/Corpus ); précédent : 001850; suivant : 001852Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
Auteurs : Roberto Marconi ; Dominique Lefebvre-Caparros ; Anne-Marie Bonnet ; Marie Vidailhet ; Bruno Dubois ; Bruno AgidSource :
- Movement Disorders [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
Abstract
The aim of this study was to provide further insight into the phenomenology and pathophysiology of monophasic and biphasic dyskinesias induced by levodopa in Parkinson's disease. For this purpose, the type, localization, severity, and timing of dyskinesias were evaluated in 15 parkinsonian patients in relation to motor disability after administration of levodopa using a video‐electromyographic recording device. Foot‐dystonia, myoclonus, and akathisia were observed in most patients. The dyskinesias started in the foot, usually on the side most affected by the disease, and spread in an “ascending wave” to the contralateral side, the trunk, and upper extremities. In a few patients, onset was axial, spreading almost instantaneously to all limbs. The dyskinesias were dystonic and ballistic at the start, and became increasingly choreic as they attained the upper limbs. Their intensity was maximal in the lower limbs, then progressively decreased, while increasing in upper limbs and head. The results indicate that there is no strict dichotomy between biphasic and monophasic dyskinesias. In other words, there is a “continuum” between the first dyskinesias and those observed during the period of maximal clinical improvement. These dyskinesias can also appear in reverse order, as if there were an “oscillator” determining a sequence of alternating patterns.
Url:
DOI: 10.1002/mds.870090103
Links to Exploration step
ISTEX:47A4FE5EDF56187C2710121CE25D3FC003824AE1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology</title><author><name sortKey="Marconi, Roberto" sort="Marconi, Roberto" uniqKey="Marconi R" first="Roberto" last="Marconi">Roberto Marconi</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurological Institute Sanatrix, Pozzilli, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lefebvre Aparros, Dominique" sort="Lefebvre Aparros, Dominique" uniqKey="Lefebvre Aparros D" first="Dominique" last="Lefebvre-Caparros">Dominique Lefebvre-Caparros</name><affiliation><mods:affiliation>Service de Neurologic C, Hǒpital B, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Bonnet, Anne Arie" sort="Bonnet, Anne Arie" uniqKey="Bonnet A" first="Anne-Marie" last="Bonnet">Anne-Marie Bonnet</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Bruno" sort="Agid, Bruno" uniqKey="Agid B" first="Bruno" last="Agid">Bruno Agid</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM U 289, Hópital de la Salpêtrière, 47 Boulevard de l'Hǒpital, 75651 Paris Cedex 13, France. Tel 33‐1‐45. 70. 37. 92; Fax 33‐1‐44. 24. 36. 58</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:47A4FE5EDF56187C2710121CE25D3FC003824AE1</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/mds.870090103</idno><idno type="url">https://api.istex.fr/document/47A4FE5EDF56187C2710121CE25D3FC003824AE1/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001851</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001851</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology</title><author><name sortKey="Marconi, Roberto" sort="Marconi, Roberto" uniqKey="Marconi R" first="Roberto" last="Marconi">Roberto Marconi</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurological Institute Sanatrix, Pozzilli, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lefebvre Aparros, Dominique" sort="Lefebvre Aparros, Dominique" uniqKey="Lefebvre Aparros D" first="Dominique" last="Lefebvre-Caparros">Dominique Lefebvre-Caparros</name><affiliation><mods:affiliation>Service de Neurologic C, Hǒpital B, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Bonnet, Anne Arie" sort="Bonnet, Anne Arie" uniqKey="Bonnet A" first="Anne-Marie" last="Bonnet">Anne-Marie Bonnet</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Bruno" sort="Agid, Bruno" uniqKey="Agid B" first="Bruno" last="Agid">Bruno Agid</name><affiliation><mods:affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</mods:affiliation></affiliation><affiliation><mods:affiliation>INSERM U 289, Hópital de la Salpêtrière, 47 Boulevard de l'Hǒpital, 75651 Paris Cedex 13, France. Tel 33‐1‐45. 70. 37. 92; Fax 33‐1‐44. 24. 36. 58</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994">1994</date><biblScope unit="volume">9</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="2">2</biblScope><biblScope unit="page" to="12">12</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">47A4FE5EDF56187C2710121CE25D3FC003824AE1</idno><idno type="DOI">10.1002/mds.870090103</idno><idno type="ArticleID">MDS870090103</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesias</term><term>Levodopa</term><term>Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to provide further insight into the phenomenology and pathophysiology of monophasic and biphasic dyskinesias induced by levodopa in Parkinson's disease. For this purpose, the type, localization, severity, and timing of dyskinesias were evaluated in 15 parkinsonian patients in relation to motor disability after administration of levodopa using a video‐electromyographic recording device. Foot‐dystonia, myoclonus, and akathisia were observed in most patients. The dyskinesias started in the foot, usually on the side most affected by the disease, and spread in an “ascending wave” to the contralateral side, the trunk, and upper extremities. In a few patients, onset was axial, spreading almost instantaneously to all limbs. The dyskinesias were dystonic and ballistic at the start, and became increasingly choreic as they attained the upper limbs. Their intensity was maximal in the lower limbs, then progressively decreased, while increasing in upper limbs and head. The results indicate that there is no strict dichotomy between biphasic and monophasic dyskinesias. In other words, there is a “continuum” between the first dyskinesias and those observed during the period of maximal clinical improvement. These dyskinesias can also appear in reverse order, as if there were an “oscillator” determining a sequence of alternating patterns.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Roberto Marconi</name><affiliations><json:string>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</json:string><json:string>Neurological Institute Sanatrix, Pozzilli, Italy</json:string></affiliations></json:item><json:item><name>Dominique Lefebvre‐Caparros</name><affiliations><json:string>Service de Neurologic C, Hǒpital B, Lille, France</json:string></affiliations></json:item><json:item><name>Anne‐Marie Bonnet</name><affiliations><json:string>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Marie Vidailhet</name><affiliations><json:string>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Bruno Dubois</name><affiliations><json:string>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Dr. Agid</name><affiliations><json:string>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</json:string><json:string>INSERM U 289, Hópital de la Salpêtrière, 47 Boulevard de l'Hǒpital, 75651 Paris Cedex 13, France. Tel 33‐1‐45. 70. 37. 92; Fax 33‐1‐44. 24. 36. 58</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Dyskinesias</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><articleId><json:string>MDS870090103</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>The aim of this study was to provide further insight into the phenomenology and pathophysiology of monophasic and biphasic dyskinesias induced by levodopa in Parkinson's disease. For this purpose, the type, localization, severity, and timing of dyskinesias were evaluated in 15 parkinsonian patients in relation to motor disability after administration of levodopa using a video‐electromyographic recording device. Foot‐dystonia, myoclonus, and akathisia were observed in most patients. The dyskinesias started in the foot, usually on the side most affected by the disease, and spread in an “ascending wave” to the contralateral side, the trunk, and upper extremities. In a few patients, onset was axial, spreading almost instantaneously to all limbs. The dyskinesias were dystonic and ballistic at the start, and became increasingly choreic as they attained the upper limbs. Their intensity was maximal in the lower limbs, then progressively decreased, while increasing in upper limbs and head. The results indicate that there is no strict dichotomy between biphasic and monophasic dyskinesias. In other words, there is a “continuum” between the first dyskinesias and those observed during the period of maximal clinical improvement. These dyskinesias can also appear in reverse order, as if there were an “oscillator” determining a sequence of alternating patterns.</abstract><qualityIndicators><score>7.412</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1367</abstractCharCount><pdfWordCount>5901</pdfWordCount><pdfCharCount>38375</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>201</abstractWordCount></qualityIndicators><title>Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology</title><refBibs><json:item><author><json:item><name>E Melamed</name></json:item></author><host><volume>36</volume><pages><last>310</last><first>308</first></pages><author></author><title>Arch Neurol</title></host><title>Early morning dystonia. A late side effect of long‐term levodopa therapy in Parkinson's disease</title></json:item><json:item><author><json:item><name>WH Poewe</name></json:item><json:item><name>AJ Lees</name></json:item><json:item><name>GM Stern</name></json:item></author><host><volume>23</volume><pages><last>78</last><first>73</first></pages><author></author><title>Ann Neurol</title></host><title>Dystonia in Parkinson's disease: clinical and pharmacological features</title></json:item><json:item><author><json:item><name>PA Nausieda</name></json:item><json:item><name>WJ Weiner</name></json:item><json:item><name>HL Klawans</name></json:item></author><host><volume>37</volume><pages><last>136</last><first>132</first></pages><author></author><title>Arch Neurol</title></host><title>Dystonic foot response of parkinsonism</title></json:item><json:item><author><json:item><name>F Lhermitte</name></json:item><json:item><name>Y Agid</name></json:item><json:item><name>JL Signoret</name></json:item><json:item><name>JM Studler</name></json:item></author><host><volume>133</volume><pages><last>308</last><first>297</first></pages><author></author><title>Rev Neurol</title></host><title>Les dyskinésies de “début et fin de dose” provoquées par la l‐dopa</title></json:item><json:item><author><json:item><name>ES Tolosa</name></json:item><json:item><name>WE Martin</name></json:item><json:item><name>HP Cohen</name></json:item></author><host><volume>2</volume><pages><last>1382</last><first>1381</first></pages><author></author><title>Lancet</title></host><title>Dyskinesia during levodopa therapy</title></json:item><json:item><author><json:item><name>MD Muenter</name></json:item><json:item><name>NS Sharpless</name></json:item><json:item><name>GM Tyce</name></json:item><json:item><name>FL Darley</name></json:item></author><host><volume>52</volume><pages><last>174</last><first>163</first></pages><author></author><title>Mayo Clin Proc</title></host><title>Patterns of dystonia (“I‐D‐I” and “D‐I‐D”) in response to l‐dopa therapy for Parkinson's disease</title></json:item><json:item><author><json:item><name>A Barbeau</name></json:item><json:item><name>H Mars</name></json:item><json:item><name>L Gillo‐Joffroy</name></json:item><json:item><name>A Arsenault</name></json:item></author><host><pages><last>120</last><first>118</first></pages><author></author><title>1‐DOPA and parkinsonism</title></host><title>A proposed classification of DOPA‐induced dyskinesias</title></json:item><json:item><author><json:item><name>J Sigwald</name></json:item><json:item><name>C Raymondeau</name></json:item></author><host><volume>112</volume><pages><last>112</last><first>103</first></pages><author></author><title>Rev Neurol</title></host><title>Les mouvements anormaux abservés au cours du traitement de la maladie de Parkinson parla l‐DOPA</title></json:item><json:item><author><json:item><name>P Rondot</name></json:item><json:item><name>C Ribadeau‐Dumas</name></json:item></author><host><volume>127</volume><pages><last>113</last><first>99</first></pages><author></author><title>Rev Neurol</title></host><title>Dopamine et mouvements anormaux</title></json:item><json:item><author><json:item><name>CD Marsden</name></json:item><json:item><name>JD Parkes</name></json:item><json:item><name>N Quinn</name></json:item></author><host><pages><last>122</last><first>96</first></pages><author></author><title>Movement disorders</title></host><title>Fluctuations of disability in Parkinson's disease–clinical aspects</title></json:item><json:item><author><json:item><name>MD Muenter</name></json:item><json:item><name>GM Tyce</name></json:item></author><host><volume>52</volume><pages><last>174</last><first>163</first></pages><author></author><title>Mayo Clin Proc</title></host><title>1‐DOPA therapy of Parkinson's disease: plasma l‐DOPA concentration, therapeutic response and side effects</title></json:item><json:item><author><json:item><name>F Lhermitte</name></json:item><json:item><name>Y Agid</name></json:item><json:item><name>C Feuerstein</name></json:item></author><host><volume>133</volume><pages><last>454</last><first>445</first></pages><author></author><title>Rev Neurol</title></host><title>Mouvements anormaux provoqués par la l‐DOPA dans la maladie de Parkinson: correlations avec les concentrations plasmatiques de DOPA et de o‐methyl‐DOPA</title></json:item><json:item><author><json:item><name>A Lees</name></json:item><json:item><name>KM Shaw</name></json:item><json:item><name>GM Stern</name></json:item></author><host><volume>12</volume><pages><first>1034</first></pages><author></author><title>Lancet</title></host><title>“Off period” dystonia and “on period” choreoathetosis in levodopa‐treated patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>Y Agid</name></json:item><json:item><name>AM Bonnet</name></json:item><json:item><name>JL Signoret</name></json:item><json:item><name>F Lhermitte</name></json:item></author><host><volume>24</volume><pages><last>410</last><first>401</first></pages><author></author><title>The extrapyramidal system and its disorders. Advances in neurology</title></host><title>Clinical, pharmacological, and biochemical approach of “onset and end‐of‐dose” dyskinesias</title></json:item><json:item><author><json:item><name>A Barbeau</name></json:item></author><host><volume>1</volume><pages><first>756</first></pages><author></author><title>Lancet</title></host><title>Diphasic dyskinesias during levodopa therapy</title></json:item><json:item><host><author></author><title>Pharmacol Ther</title></host></json:item><json:item><author><json:item><name>E Pourcher</name></json:item><json:item><name>AM Bonnet</name></json:item><json:item><name>J Kefalos</name></json:item><json:item><name>B Dubois</name></json:item><json:item><name>Y Agid</name></json:item></author><host><volume>4</volume><pages><last>201</last><first>195</first></pages><author></author><title>Mov Disord</title></host><title>Effects of ethybenztropine and diazepam on levodopa‐induced diphasic dyskinesia in Parkinson's disease</title></json:item><json:item><author><json:item><name>D Kidron</name></json:item><json:item><name>E Melamed</name></json:item></author><host><volume>37</volume><pages><last>1011</last><first>1009</first></pages><author></author><title>Neurology</title></host><title>Forms of dystonia in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>MR Luquin</name></json:item><json:item><name>O Scipioni</name></json:item><json:item><name>J Vaamonde</name></json:item><json:item><name>O Gershanick</name></json:item><json:item><name>JA Obeso</name></json:item></author><host><volume>7</volume><pages><last>124</last><first>117</first></pages><author></author><title>Mov Disord</title></host><title>Levodopa‐induced dyskinesias in Parkinson's disease: clinical and pharmacological classification</title></json:item><json:item><author><json:item><name>JG Nutt</name></json:item><json:item><name>WR Woodward</name></json:item><json:item><name>JP Hammerstad</name></json:item><json:item><name>JH Carter</name></json:item><json:item><name>JL Anderson</name></json:item></author><host><volume>310</volume><pages><last>488</last><first>483</first></pages><author></author><title>N Engl J Med</title></host><title>The “on‐off” phenomenon in Parkinson's disease. Relation to levodopa absorption and transport</title></json:item><json:item><author><json:item><name>F Lhermitte</name></json:item><json:item><name>Y Agid</name></json:item><json:item><name>JL Signoret</name></json:item></author><host><volume>35</volume><pages><last>263</last><first>261</first></pages><author></author><title>Arch Neurol</title></host><title>Onset and end‐of‐dose levodopa‐induced dyskinesias</title></json:item><json:item><author><json:item><name>S Fahn</name></json:item></author><host><pages><last>145</last><first>123</first></pages><author></author><title>Movement disorders</title></host><title>Fluctuation of disability in Parkinson's disease: pathophysiological aspects</title></json:item><json:item><author><json:item><name>MF Folstein</name></json:item><json:item><name>SE Folstein</name></json:item><json:item><name>PR McHugh</name></json:item></author><host><volume>12</volume><pages><last>198</last><first>189</first></pages><author></author><title>J Psychiatr Res</title></host><title>Mini‐Mental State: a practical method for grading the cognitive state of patients for the clinician</title></json:item><json:item><author><json:item><name>M Esteguy</name></json:item><json:item><name>AM Bonnet</name></json:item><json:item><name>J Kefalos</name></json:item><json:item><name>F Lhermitte</name></json:item><json:item><name>Y Agid</name></json:item></author><host><volume>141</volume><pages><last>415</last><first>413</first></pages><author></author><title>Rev Neurol</title></host><title>Le test à la l‐Dopa dans la maladie de Parkinson</title></json:item><json:item><author><json:item><name>S Fahn</name></json:item><json:item><name>RL Elton</name></json:item></author><host><volume>II</volume><pages><last>163</last><first>153</first></pages><author></author><title>Recent developments in Parkinson's disease</title></host><title>Members of the UPDRS development committee. Unified Parkinson's disease rating scale</title></json:item><json:item><author><json:item><name>D Kidron</name></json:item><json:item><name>E Melamed</name></json:item></author><host><volume>37</volume><pages><last>1011</last><first>1009</first></pages><author></author><title>Neurology</title></host><title>Forms of dystonia in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>LG Cohen</name></json:item><json:item><name>M Hallet</name></json:item></author><host><volume>38</volume><pages><last>1012</last><first>1005</first></pages><author></author><title>Neurology</title></host><title>Hand cramps clinical features and electromyographic patterns in a focal dystonia</title></json:item><json:item><host><author></author><title>Weiner WJ,Lang AE, eds.Movement disorders: a comprehensive survey.Mount Kisco, NY: Futura Publishing Company,1989.</title></host></json:item><json:item><author><json:item><name>PD Thompson</name></json:item><json:item><name>A Berardelli</name></json:item><json:item><name>JC Rothwell</name></json:item></author><host><volume>111</volume><pages><last>244</last><first>223</first></pages><author></author><title>Brain</title></host><title>The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement</title></json:item><json:item><host><author></author><title>Rondot P,Bathien N,Ziegler M, eds.Les mouvements anormaux.Paris: Masson,1988.</title></host></json:item><json:item><author><json:item><name>DE Wilkins</name></json:item><json:item><name>M Hallet</name></json:item><json:item><name>A Berardelli</name></json:item><json:item><name>T Walshe</name></json:item><json:item><name>N Alvarez</name></json:item></author><host><volume>34</volume><pages><last>903</last><first>898</first></pages><author></author><title>Neurology</title></host><title>Physiologic analysis of the myoclonus of Alzheimer's disease</title></json:item><json:item><author><json:item><name>AE Lang</name></json:item><json:item><name>K Johnson</name></json:item></author><host><volume>37</volume><pages><last>481</last><first>477</first></pages><author></author><title>Neurology</title></host><title>Akathisia in idiopathic Parkinson's disease</title></json:item><json:item><author><json:item><name>HL Klawans</name></json:item><json:item><name>C Goetz</name></json:item><json:item><name>D Bergen</name></json:item></author><host><volume>32</volume><pages><last>334</last><first>331</first></pages><author></author><title>Arch Neurol</title></host><title>Levodopa‐induced myoclonus</title></json:item><json:item><author><json:item><name>WRG Gibb</name></json:item><json:item><name>AJ Lees</name></json:item></author><host><volume>49</volume><pages><last>866</last><first>861</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>The clinical phenomenon of akathisia</title></json:item><json:item><author><json:item><name>RE Burke</name></json:item><json:item><name>UJ Kang</name></json:item><json:item><name>J Jankovic</name></json:item><json:item><name>LG Miller</name></json:item><json:item><name>S Fahn</name></json:item></author><host><volume>4</volume><pages><last>175</last><first>157</first></pages><author></author><title>Mov Disord</title></host><title>Tardive akathisia an analysis of clinical features and response to open therapeutic trials</title></json:item><json:item><author><json:item><name>JI Merello</name></json:item><json:item><name>AJ Lees</name></json:item></author><host><volume>55</volume><pages><last>1026</last><first>1024</first></pages><author></author><title>J Neurol Neurosurg Psychiatry</title></host><title>Beginning‐of‐dose motor deterioration following the acute deterioration of levodopa and apomorphine in Parkinson's disease</title></json:item><json:item><author><json:item><name>JI Nagy</name></json:item><json:item><name>T Lee</name></json:item><json:item><name>P Seeman</name></json:item><json:item><name>HC Fibiger</name></json:item></author><host><volume>274</volume><pages><last>281</last><first>278</first></pages><author></author><title>Nature</title></host><title>Direct evidence for presynaptic and postsynaptic dopamine receptors in brain</title></json:item><json:item><author><json:item><name>JC Schwartz</name></json:item><json:item><name>J Costentin</name></json:item><json:item><name>MP Martres</name></json:item><json:item><name>P Protais</name></json:item><json:item><name>M Baudry</name></json:item></author><host><volume>17</volume><pages><last>685</last><first>665</first></pages><author></author><title>Neuropharmacology</title></host><title>Modulation of receptor mechanisms in the CNS hyper‐and hyposensitivity to catecholamines</title></json:item><json:item><author><json:item><name>JG Nutt</name></json:item><json:item><name>ST Gaucher</name></json:item><json:item><name>WR Woodward</name></json:item></author><host><volume>38</volume><pages><last>1557</last><first>1553</first></pages><author></author><title>Neurology</title></host><title>Does an inhibitory action of levodopa contribute to motor fluctuations?</title></json:item><json:item><author><json:item><name>HL Klawans</name></json:item><json:item><name>C Goetz</name></json:item><json:item><name>PA Nausieda</name></json:item><json:item><name>WJ Weiner</name></json:item></author><host><volume>2</volume><pages><last>129</last><first>125</first></pages><author></author><title>Ann neurol</title></host><title>Levodopa‐induced dopamine receptor hypersensitivity</title></json:item><json:item><author><json:item><name>Y Agid</name></json:item><json:item><name>AM Bonnet</name></json:item><json:item><name>M Ruberg</name></json:item><json:item><name>F Javoy‐Agid</name></json:item></author><host><pages><last>159</last><first>145</first></pages><author></author><title>Dyskinesia–research and treatment</title></host><title>Pathophysiology of levodopa induced abnormal involuntary movements</title></json:item><json:item><author><json:item><name>AM Graybiel</name></json:item><json:item><name>E Hirsh</name></json:item><json:item><name>Y Agid</name></json:item></author><host><volume>84</volume><pages><last>307</last><first>303</first></pages><author></author><title>Proc Natl Acad Sci USA</title></host><title>Differences in tyrosine hydroxylase‐like immunoreactivity characterize the mesostriatal innervation of striosomes and extrastriosomal matrix at maturity</title></json:item><json:item><author><json:item><name>AM Graybiel</name></json:item><json:item><name>EC Hirsch</name></json:item><json:item><name>Y Agid</name></json:item></author><host><volume>53</volume><pages><last>92</last><first>17</first></pages><author></author><title>Parkinson's disease: anatomy, pathology, and therapy. Advances in Neurology</title></host><title>The nigrostriatal system in Parkinson's disease</title></json:item><json:item><author><json:item><name>SJ Kish</name></json:item><json:item><name>HK Shannak</name></json:item><json:item><name>O Hornykiewicz</name></json:item></author><host><volume>318</volume><pages><last>880</last><first>876</first></pages><author></author><title>N Engl J Med</title></host><title>Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease–pathophysiolgic and clinical implications</title></json:item><json:item><author><json:item><name>H Kunzle</name></json:item></author><host><volume>88</volume><pages><last>209</last><first>195</first></pages><author></author><title>Brain Res</title></host><title>Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study in Macaca fascicularis</title></json:item><json:item><author><json:item><name>GE Alexander</name></json:item><json:item><name>MD Crutcher</name></json:item></author><host><volume>13</volume><pages><last>271</last><first>266</first></pages><author></author><title>Trends Neurosci</title></host><title>Functional architecture of basal ganglia circuits and neural substrates of parallel processing</title></json:item><json:item><author><json:item><name>AM Graybiel</name></json:item><json:item><name>CW Ragsdale</name></json:item></author><host><volume>75</volume><pages><last>5726</last><first>5723</first></pages><author></author><title>Proc Natl Acad Sci USA</title></host><title>Histochemically distinct compartments in striatum of human, monkey, and cat demonstrated by acetylthiocholinesterase staining</title></json:item><json:item><author><json:item><name>P Gaspar</name></json:item><json:item><name>F Javoy‐Agid</name></json:item><json:item><name>A Ploska</name></json:item><json:item><name>Y Agid</name></json:item></author><host><volume>34</volume><pages><last>283</last><first>278</first></pages><author></author><title>J Neurochem</title></host><title>Regional distribution of neurotransmitter synthesizing enzymes in the basal ganglia of human brain</title></json:item><json:item><author><json:item><name>CR Gerfen</name></json:item></author><host><volume>15</volume><pages><last>139</last><first>133</first></pages><author></author><title>Trends Neurosci</title></host><title>The neostriatal mosaic multiple levels of compartmental organization</title></json:item><json:item><author><json:item><name>CR Gerfen</name></json:item><json:item><name>TM Engber</name></json:item><json:item><name>LC Mahan</name></json:item></author><host><volume>250</volume><pages><last>1432</last><first>1429</first></pages><author></author><title>Science</title></host><title>D1 and D2 dopamine receptor‐regulated gene expression of striatonigral and striatopallidal neurons</title></json:item><json:item><author><json:item><name>MJ Besson</name></json:item><json:item><name>AM Graybiel</name></json:item><json:item><name>MA Natsuk</name></json:item></author><host><volume>26</volume><pages><last>119</last><first>101</first></pages><author></author><title>Neuroscience</title></host><title>[3H]SCH23390 binding to D1 dopamine receptors in the basal ganglia of the cat and primate: delineation of striosomal compartments and pallidal and nigral subdivisions</title></json:item><json:item><author><json:item><name>Y Agid</name></json:item><json:item><name>F Javoy‐Agid</name></json:item><json:item><name>M Ruberg</name></json:item></author><host><volume>2</volume><pages><last>230</last><first>166</first></pages><author></author><title>Movement disorders</title></host><title>Biochemistry of neurotransmitters in Parkinson's disease</title></json:item><json:item><author><json:item><name>MR Luquin</name></json:item><json:item><name>J Laguna</name></json:item><json:item><name>JA Obeso</name></json:item></author><host><volume>31</volume><pages><last>554</last><first>551</first></pages><author></author><title>Ann Neurol</title></host><title>Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys</title></json:item><json:item><author><json:item><name>S Boyce</name></json:item><json:item><name>NMJ Rupniak</name></json:item><json:item><name>MJ Stevenson</name></json:item><json:item><name>SD Iversen</name></json:item></author><host><volume>40</volume><pages><last>933</last><first>927</first></pages><author></author><title>Neurology</title></host><title>Differential effects of D1 and D2 agonists in MPTP‐treated primates: functional implications for Parkinson's disease</title></json:item><json:item><author><json:item><name>IJ Mitchell</name></json:item><json:item><name>R Luquin</name></json:item><json:item><name>S Boyce</name></json:item></author><host><volume>5</volume><pages><last>54</last><first>49</first></pages><author></author><title>Mov Disord</title></host><title>Neural mechanisms of dystonia evidence from a 2‐deoxyglucose uptake study in a primate model of dopamine agonist‐induced dystonia</title></json:item><json:item><author><json:item><name>MM Mouradian</name></json:item><json:item><name>IJE Heuser</name></json:item><json:item><name>F Baronti</name></json:item><json:item><name>G Fabbrini</name></json:item><json:item><name>JL Juncos</name></json:item><json:item><name>TN Chase</name></json:item></author><host><volume>25</volume><pages><last>526</last><first>523</first></pages><author></author><title>Ann Neurol</title></host><title>Pathogenesis of dyskinesias in Parkinson's disease</title></json:item><json:item><author><json:item><name>AR Crossman</name></json:item></author><host><volume>5</volume><pages><last>108</last><first>100</first></pages><author></author><title>Mov Disord</title></host><title>A hypothesis on the pathophysiological mechanisms that underlie levodopa‐ or dopamine agonistinduced dyskinesia in Parkinson's disease implications for future strategies in treatment</title></json:item><json:item><author><json:item><name>AR Crossman</name></json:item><json:item><name>IJ Mitchell</name></json:item><json:item><name>MA Sambrook</name></json:item><json:item><name>A Jackson</name></json:item></author><host><volume>111</volume><pages><last>1233</last><first>1211</first></pages><author></author><title>Brain</title></host><title>Chorea and myoclonus in the monkey induced by gammaaminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>9</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>11</total><last>12</last><first>2</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Article</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>1994</publicationDate><copyrightDate>1994</copyrightDate><doi><json:string>10.1002/mds.870090103</json:string></doi><id>47A4FE5EDF56187C2710121CE25D3FC003824AE1</id><score>0.18908069</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/47A4FE5EDF56187C2710121CE25D3FC003824AE1/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/47A4FE5EDF56187C2710121CE25D3FC003824AE1/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/47A4FE5EDF56187C2710121CE25D3FC003824AE1/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 1994 Movement Disorder Society</p></availability><date>1994</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology</title><author xml:id="author-1"><persName><forename type="first">Roberto</forename><surname>Marconi</surname></persName><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation><affiliation>Neurological Institute Sanatrix, Pozzilli, Italy</affiliation></author><author xml:id="author-2"><persName><forename type="first">Dominique</forename><surname>Lefebvre‐Caparros</surname></persName><affiliation>Service de Neurologic C, Hǒpital B, Lille, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Anne‐Marie</forename><surname>Bonnet</surname></persName><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Marie</forename><surname>Vidailhet</surname></persName><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Bruno</forename><surname>Dubois</surname></persName><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation></author><author xml:id="author-6"><persName><surname>Agid</surname></persName><roleName type="degree">Dr.</roleName><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation><affiliation>INSERM U 289, Hópital de la Salpêtrière, 47 Boulevard de l'Hǒpital, 75651 Paris Cedex 13, France. Tel 33‐1‐45. 70. 37. 92; Fax 33‐1‐44. 24. 36. 58</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994"></date><biblScope unit="volume">9</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="2">2</biblScope><biblScope unit="page" to="12">12</biblScope></imprint></monogr><idno type="istex">47A4FE5EDF56187C2710121CE25D3FC003824AE1</idno><idno type="DOI">10.1002/mds.870090103</idno><idno type="ArticleID">MDS870090103</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1994</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The aim of this study was to provide further insight into the phenomenology and pathophysiology of monophasic and biphasic dyskinesias induced by levodopa in Parkinson's disease. For this purpose, the type, localization, severity, and timing of dyskinesias were evaluated in 15 parkinsonian patients in relation to motor disability after administration of levodopa using a video‐electromyographic recording device. Foot‐dystonia, myoclonus, and akathisia were observed in most patients. The dyskinesias started in the foot, usually on the side most affected by the disease, and spread in an “ascending wave” to the contralateral side, the trunk, and upper extremities. In a few patients, onset was axial, spreading almost instantaneously to all limbs. The dyskinesias were dystonic and ballistic at the start, and became increasingly choreic as they attained the upper limbs. Their intensity was maximal in the lower limbs, then progressively decreased, while increasing in upper limbs and head. The results indicate that there is no strict dichotomy between biphasic and monophasic dyskinesias. In other words, there is a “continuum” between the first dyskinesias and those observed during the period of maximal clinical improvement. These dyskinesias can also appear in reverse order, as if there were an “oscillator” determining a sequence of alternating patterns.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Dyskinesias</term></item><item><term>Levodopa</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1994">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/47A4FE5EDF56187C2710121CE25D3FC003824AE1/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v9:1</doi><numberingGroup><numbering type="journalVolume" number="9">9</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="1994">1994</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="3" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870090103</doi><idGroup><id type="unit" value="MDS870090103"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1994 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:HeaderRef result:HeaderRef" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2</numbering><numbering type="pageLast">12</numbering></numberingGroup><correspondenceTo>INSERM U 289, Hópital de la Salpêtrière, 47 Boulevard de l'Hǒpital, 75651 Paris Cedex 13, France. Tel 33‐1‐45. 70. 37. 92; Fax 33‐1‐44. 24. 36. 58</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870090103.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="6"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="58"></count></countGroup><titleGroup><title type="main" xml:lang="en">Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology</title><title type="short" xml:lang="en">LEVODOPA‐INDUCED DYSKINESIAS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Roberto</givenNames><familyName>Marconi</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Dominique</givenNames><familyName>Lefebvre‐Caparros</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anne‐Marie</givenNames><familyName>Bonnet</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Marie</givenNames><familyName>Vidailhet</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Bruno</givenNames><familyName>Dubois</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Yves</givenNames><familyName>Agid</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Service de Neurologic C, Hǒpital B, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="IT" type="organization"><unparsedAffiliation>Neurological Institute Sanatrix, Pozzilli, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Dyskinesias</keyword><keyword xml:id="kwd2">Levodopa</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The aim of this study was to provide further insight into the phenomenology and pathophysiology of monophasic and biphasic dyskinesias induced by levodopa in Parkinson's disease. For this purpose, the type, localization, severity, and timing of dyskinesias were evaluated in 15 parkinsonian patients in relation to motor disability after administration of levodopa using a video‐electromyographic recording device. Foot‐dystonia, myoclonus, and akathisia were observed in most patients. The dyskinesias started in the foot, usually on the side most affected by the disease, and spread in an “ascending wave” to the contralateral side, the trunk, and upper extremities. In a few patients, onset was axial, spreading almost instantaneously to all limbs. The dyskinesias were dystonic and ballistic at the start, and became increasingly choreic as they attained the upper limbs. Their intensity was maximal in the lower limbs, then progressively decreased, while increasing in upper limbs and head. The results indicate that there is no strict dichotomy between biphasic and monophasic dyskinesias. In other words, there is a “continuum” between the first dyskinesias and those observed during the period of maximal clinical improvement. These dyskinesias can also appear in reverse order, as if there were an “oscillator” determining a sequence of alternating patterns.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>LEVODOPA‐INDUCED DYSKINESIAS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology</title></titleInfo><name type="personal"><namePart type="given">Roberto</namePart><namePart type="family">Marconi</namePart><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation><affiliation>Neurological Institute Sanatrix, Pozzilli, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dominique</namePart><namePart type="family">Lefebvre‐Caparros</namePart><affiliation>Service de Neurologic C, Hǒpital B, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anne‐Marie</namePart><namePart type="family">Bonnet</namePart><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marie</namePart><namePart type="family">Vidailhet</namePart><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bruno</namePart><namePart type="family">Dubois</namePart><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Agid</namePart><affiliation>INSERM U 289 and Clinique de Neurologie et Neuropsychologie, Hópital de la Salpêtrière, Paris, France</affiliation><affiliation>INSERM U 289, Hópital de la Salpêtrière, 47 Boulevard de l'Hǒpital, 75651 Paris Cedex 13, France. Tel 33‐1‐45. 70. 37. 92; Fax 33‐1‐44. 24. 36. 58</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1994</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">6</extent><extent unit="tables">1</extent><extent unit="references">58</extent></physicalDescription><abstract lang="en">The aim of this study was to provide further insight into the phenomenology and pathophysiology of monophasic and biphasic dyskinesias induced by levodopa in Parkinson's disease. For this purpose, the type, localization, severity, and timing of dyskinesias were evaluated in 15 parkinsonian patients in relation to motor disability after administration of levodopa using a video‐electromyographic recording device. Foot‐dystonia, myoclonus, and akathisia were observed in most patients. The dyskinesias started in the foot, usually on the side most affected by the disease, and spread in an “ascending wave” to the contralateral side, the trunk, and upper extremities. In a few patients, onset was axial, spreading almost instantaneously to all limbs. The dyskinesias were dystonic and ballistic at the start, and became increasingly choreic as they attained the upper limbs. Their intensity was maximal in the lower limbs, then progressively decreased, while increasing in upper limbs and head. The results indicate that there is no strict dichotomy between biphasic and monophasic dyskinesias. In other words, there is a “continuum” between the first dyskinesias and those observed during the period of maximal clinical improvement. These dyskinesias can also appear in reverse order, as if there were an “oscillator” determining a sequence of alternating patterns.</abstract><subject lang="en"><genre>keywords</genre><topic>Dyskinesias</topic><topic>Levodopa</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>2</start><end>12</end><total>11</total></extent></part></relatedItem><identifier type="istex">47A4FE5EDF56187C2710121CE25D3FC003824AE1</identifier><identifier type="DOI">10.1002/mds.870090103</identifier><identifier type="ArticleID">MDS870090103</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1994 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001851 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001851 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:47A4FE5EDF56187C2710121CE25D3FC003824AE1
|texte= Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
}}
| This area was generated with Dilib version V0.6.29. |  |